{"product_id":"ldn-book-volume-two","title":"Ldn Book Volume Two By Elsegood , Linda","description":"\u003cp\u003e\u003cstrong\u003eA comprehensive examination of Low Dose Naltrexone – a little-known drug with big potential\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eNew drug [LDN] raises hopes of reversing memory loss in old age \u003c\/strong\u003e\u003cem\u003e\u003cspan style=\"font-weight: 400;\"\u003ethe Guardian\u003c\/span\u003e\u003c\/em\u003e\u003c\/p\u003e\u003cp\u003e\u003cspan style=\"font-weight: 400;\"\u003eA drug that is simultaneously affordable, devoid of severe side effects, and applicable to a wide range of diseases is not often found in the modern pharmaceutical landscape. But as medical professionals and researchers alike continue to discover, Low Dose Naltrexone (LDN) boasts this remarkable combination.\u003c\/span\u003e\u003c\/p\u003e\u003cp\u003e\u003cspan style=\"font-weight: 400;\"\u003eExpanding on the information presented in \u003c\/span\u003e\u003cstrong\u003e\u003cem\u003eThe LDN Book, Volume 1\u003c\/em\u003e\u003c\/strong\u003e\u003cspan style=\"font-weight: 400;\"\u003e – which showcased LDN’s efficacy in treating conditions such as lupus, thyroiditis, autism spectrum disorder, and chronic fatigue – \u003c\/span\u003e\u003cstrong\u003e\u003cem\u003eVolume 2\u003c\/em\u003e\u003c\/strong\u003e\u003cspan style=\"font-weight: 400;\"\u003e highlights the latest clinical trials, case studies and research on LDN. More than a dozen medical professionals explain how they are using LDN to help patients suffering from:\u003c\/span\u003e\u003c\/p\u003e\u003cul\u003e\n\u003cli style=\"font-weight: 400;\" aria-level=\"1\"\u003e\u003cspan style=\"font-weight: 400;\"\u003eChronic pain\u003c\/span\u003e\u003c\/li\u003e\n\u003cli style=\"font-weight: 400;\" aria-level=\"1\"\u003e\u003cspan style=\"font-weight: 400;\"\u003eParkinson’s disease\u003c\/span\u003e\u003c\/li\u003e\n\u003cli style=\"font-weight: 400;\" aria-level=\"1\"\u003e\u003cspan style=\"font-weight: 400;\"\u003eDermatologic conditions\u003c\/span\u003e\u003c\/li\u003e\n\u003cli style=\"font-weight: 400;\" aria-level=\"1\"\u003e\u003cspan style=\"font-weight: 400;\"\u003eTraumatic brain injury \u003c\/span\u003e\u003c\/li\u003e\n\u003cli style=\"font-weight: 400;\" aria-level=\"1\"\u003e\u003cspan style=\"font-weight: 400;\"\u003eLyme disease and more.\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003e\u003cstrong\u003e\u003cem\u003eVolume 1\u003c\/em\u003e\u003c\/strong\u003e\u003cspan style=\"font-weight: 400;\"\u003e and \u003c\/span\u003e\u003cstrong\u003e\u003cem\u003eVolume 2\u003c\/em\u003e\u003c\/strong\u003e\u003cspan style=\"font-weight: 400;\"\u003e have been edited by Linda Elsegood, founder of the UK-based LDN Research Trust. Through the Trust and her work on the LDN books, Linda has connected \u003c\/span\u003e\u003cspan style=\"font-weight: 400;\"\u003ethousands of patients, doctors and pharmacists around the world with information, articles and patient stories about LDN. \u003c\/span\u003e\u003cstrong\u003e\u003cem\u003eThe LDN Book, Volume 2\u003c\/em\u003e\u003c\/strong\u003e\u003cspan style=\"font-weight: 400;\"\u003e is a fantastic resource for practitioners, pharmacists and patients and a renewed call for further research on the healing potential of this beneficial drug.\u003c\/span\u003e\u003c\/p\u003e","brand":"MediaPlace","offers":[{"title":"Default Title","offer_id":57559598432638,"sku":"NW9781603589901","price":21.95,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1379\/1261\/files\/9781603589901.jpg?v=1783371513","url":"https:\/\/mediaplace.com\/en-eu\/products\/ldn-book-volume-two","provider":"MediaPlace","version":"1.0","type":"link"}